<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">Drugs that provide significant improvements in tolerability or effectiveness in the treatment, diagnosis, or prevention of serious conditions when compared to standard applications may be granted a Priority Review designation, which shortens the anticipated review time from 10 months to 6 months.
 <xref rid="bib12" ref-type="bibr">
  <sup>12</sup>
 </xref> Drugs in development that have recently been given a Priority Review designation include capmatinib for patients with certain nonâ€“small cell lung cancers, and belantamab mafodotin for patients with relapsed or refractory multiple myeloma.
 <xref rid="bib13" ref-type="bibr">
  <sup>13</sup>
 </xref> There was a total of 48 approvals for New Drug Applications and 13 approvals for Biologics License Applications given the Priority Review designation in the calendar year of 2018, the last year of available cumulative information.
 <xref rid="bib14" ref-type="bibr">
  <sup>14</sup>
 </xref>
</p>
